Title : mPRĪ± mediates P4/Org OD02-0 to improve the sensitivity of lung adenocarcinoma to EGFR-TKIs via the EGFR-SRC-ERK1/2 pathway.

Pub. Date : 2020 Feb

PMID : 31777985






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The discovery of epidermal growth factor receptor (EGFR) mutations has made EGFR tyrosine kinase inhibitors (EGFR-TKIs) a milestone in the treatment for advanced non-small cell lung cancer (NSCLC). Tyrosine epidermal growth factor receptor Homo sapiens
2 The discovery of epidermal growth factor receptor (EGFR) mutations has made EGFR tyrosine kinase inhibitors (EGFR-TKIs) a milestone in the treatment for advanced non-small cell lung cancer (NSCLC). Tyrosine epidermal growth factor receptor Homo sapiens
3 The discovery of epidermal growth factor receptor (EGFR) mutations has made EGFR tyrosine kinase inhibitors (EGFR-TKIs) a milestone in the treatment for advanced non-small cell lung cancer (NSCLC). Tyrosine epidermal growth factor receptor Homo sapiens
4 The discovery of epidermal growth factor receptor (EGFR) mutations has made EGFR tyrosine kinase inhibitors (EGFR-TKIs) a milestone in the treatment for advanced non-small cell lung cancer (NSCLC). Tyrosine epidermal growth factor receptor Homo sapiens